Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy - Wikidata - wikimedia - TriplyDB

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy

http://www.wikidata.org/entity/Q35214949

about

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015 Using age-specific mortality of HIV infected persons to predict anti-retroviral treatment need: a comparative analysis of data from five African population-based cohort studies.Economic returns to investment in AIDS treatment in low and middle income countries.Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.Effective coverage for antiretroviral therapy in a Ugandan district with a decentralized model of care.Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.Antiretroviral treatment coverage in a rural district in Tanzania--a modeling study using empirical data.Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults Antiretroviral therapy needs: the effect of changing global guidelines.The Spectrum projection package: improvements in estimating incidence by age and sex, mother-to-child transmission, HIV progression in children and double orphans.Under-5 mortality due to HIV: regional levels and 1990-2009 trends.Impact and Cost of the HIV/AIDS National Strategic Plan for Mozambique, 2015-2019--Projections with the Spectrum/Goals Model Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa.Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention.Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.The 2009 HIV and AIDS estimates and projections: methods, tools and analyses.

P2860

Q28391248-D892221D-C07A-4184-99B0-C5F8168BFBA4 Q30560888-491B9D8A-F647-4095-887C-F1ED2F21C0BB Q31036894-7E3B157B-6BF8-4E23-B88A-F411807BDBBA Q34081339-B31D9E29-CA44-4333-9637-22C7763C664A Q34667707-5395F4C1-0979-4E94-B01F-393A8CF5A4F6 Q34920087-1520883D-CC5C-45EC-B1FB-E0E9BE2C43F1 Q35007321-EE040A7C-5D27-41D6-AE82-BC31A261F235 Q35146412-1FA42C74-A758-4AE5-BE2B-B97A401C60E9 Q35214935-BCAD9F8E-5A7A-4FEA-9729-4EC7EDA63061 Q35214939-7493CFB4-AC38-4B24-8016-D3EB3A5E4885 Q35215002-9A142C2A-EBE2-4841-80DB-6BA458FF17B9 Q35215021-DCAB1933-306B-4D2C-9C7D-9D7AF2E919F8 Q35840668-B8BC8E52-C310-4D3F-BD8A-6CE86201B039 Q36301925-0AEA0933-E8F8-4D9B-ADD9-17806928D929 Q36888158-89AADCD6-9761-4750-8296-F172C4489B08 Q37305607-0FB9A4BB-0E69-413A-950C-A0B95083C8F7 Q37494332-915CF7FE-AFD1-47E2-9CC3-E58FF8079F6E Q55461742-6AFCDFC9-72BB-402B-A156-4B7125F5A118

P2860

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy

http://www.wikidata.org/entity/Q35214949

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Derivation of parameters used ...... ival on antiretroviral therapy

@ast

Derivation of parameters used ...... ival on antiretroviral therapy

@en

type

label

Derivation of parameters used ...... ival on antiretroviral therapy

@ast

Derivation of parameters used ...... ival on antiretroviral therapy

@en

prefLabel

Derivation of parameters used ...... ival on antiretroviral therapy

@ast

Derivation of parameters used ...... ival on antiretroviral therapy

@en

P1433

Q35214949-AE580936-4F60-4891-84E8-5692B9BD5E1E

P1476

Q35214949-37874F98-BF4B-4A62-8F8E-15A38D36644D

P2093

Q35214949-507AD55B-8C61-4548-AE41-622800E20AEB

Q35214949-5DCFE7B8-0919-4D1C-8A58-77DF8E3B2FF4

Q35214949-7C1E0D96-1E3B-45F2-95CD-B89A898E6AD6

Q35214949-8C8D2D99-4AD5-4A4B-B05C-81F520496D0D

Q35214949-9DBFA72D-F32C-41A3-9693-0109105FEEB8

Q35214949-F0EE6880-F06D-4FFA-97C0-571B6EF7DD4F

P2860

Q35214949-03872C41-67F1-4F48-BB17-0010D2A7CA4E

Q35214949-08A1ED33-953C-4895-9EB3-B3B8D9B26C26

Q35214949-1B4393FF-0B51-4286-A26D-5CBB0804C047

Q35214949-256AF5E3-CC1C-478A-8323-9B7867A01244

Q35214949-2CE3BD72-1D66-4973-A18A-C097144161DB

Q35214949-39E78752-A6CF-43F2-B850-223970F2B5F2

Q35214949-4C204CC0-3957-48B4-841C-F165245F8AF7

Q35214949-572A53BE-D93A-4AC5-BE3C-7A787FEA0C43

Q35214949-59C12B91-19A1-4743-8652-A8B920210C25

Q35214949-62E5418E-58B4-4B96-984A-0E69CD99B78C

P304

Q35214949-63E643C6-E2C4-4653-81DE-CDB7E2AB7A9D

P31

Q35214949-AD19C5C3-1129-48E6-BB3A-BA6D71FB6889

P356

Q35214949-208AB458-0DE6-40E6-B569-8BF08DB3EB21

P478

Q35214949-8A88F09A-0DAC-4FC8-B6B1-BD3284DF2053

P50

Q35214949-20BF5C73-BB9E-40BE-B9D8-4FDA3CEFFBA9

P577

Q35214949-06C46D6B-D53E-4A17-A600-432BDE0A9F6C

P5875

Q35214949-5977F14B-3B2C-46F3-BD8F-B1F9053A41BA

P698

Q35214949-E0C77104-7FDC-42D1-BCCB-5BAA8695B4CD

P921

Q35214949-31E401D4-53B3-47E4-8500-B6BB660705F5

P932

Q35214949-F8698D65-71B0-485D-B303-69E12779B67B

P356

STI.2010.044255

P1433

Sexually Transmitted Infections

P1476

Derivation of parameters used ...... ival on antiretroviral therapy

@en

P2093

Charlotte Lewden

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Tassie

http://www.w3.org/2001/XMLSchema#string

John Stover

http://www.w3.org/2001/XMLSchema#string

Martin W G Brinkhof

http://www.w3.org/2001/XMLSchema#string

Mary Mahy

http://www.w3.org/2001/XMLSchema#string

Yves Souteyrand

http://www.w3.org/2001/XMLSchema#string

P2860

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults

Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009.

Using estimation and projection package and Spectrum for Jamaica's national HIV estimates and targets.

The Spectrum projection package: improvements in estimating incidence by age and sex, mother-to-child transmission, HIV progression in children and double orphans.

Under-5 mortality due to HIV: regional levels and 1990-2009 trends.

Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach.

P304

ii28-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/STI.2010.044255

http://www.w3.org/2001/XMLSchema#string

P478

86 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

François Dabis

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49634756

http://www.w3.org/2001/XMLSchema#string

P698

21106512

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3173808

http://www.w3.org/2001/XMLSchema#string